ZNTL Stock Price, Zentalis Pharmaceuticals Quote, Chart

Market Summary

USD11.75-0.79

Market Closed

-6.30%

ZNTL Stock Price

View Fullscreen

ZNTL RSI Chart

ZNTL Valuation

Market Cap

834.4M

Price/Earnings (Trailing)

-3.81

EV/EBITDA

-3.88

Price/Free Cashflow

-3.95

MarketCap/EBT

-4.05

ZNTL Price/Sales (Trailing)

ZNTL Profitability

Return on Equity

-47.72%

Return on Assets

-39.27%

Free Cashflow Yield

-25.3%

ZNTL Fundamentals

ZNTL Earnings

Earnings (TTM)

-218.9M

Earnings Growth (Yr)

115.93%

Earnings Growth (Qtr)

116.53%

Breaking Down ZNTL Revenue

Last 7 days

0.3%

Last 30 days

-12.4%

Last 90 days

8.5%

Trailing 12 Months

-56.3%

How does ZNTL drawdown profile look like?

ZNTL Financial Health

Current Ratio

9.19

ZNTL Investor Care

Shares Dilution (1Y)

19.39%

Diluted EPS (TTM)

-3.3

Tracking the Latest Insider Buys and Sells of Zentalis Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 09, 2024	hausman diana	sold	-42,352	12.62	-3,356	chief medical officer
Feb 12, 2024	epperly melissa b,	sold	-29,435	11.44	-2,573	chief financial officer
Feb 12, 2024	gallagher cam	sold	-13,419	11.44	-1,173	president
Feb 02, 2024	paul andrea	sold	-38,197	11.54	-3,310	chief legal officer
Feb 02, 2024	epperly melissa b,	sold	-100,040	11.54	-8,669	chief financial officer
Feb 02, 2024	gallagher cam	sold	-133,310	11.54	-11,552	president
Feb 02, 2024	lackner mark	sold	-18,290	11.54	-1,585	chief scientific officer
Feb 01, 2024	hausman diana	acquired	-	-	337,500	chief medical officer
Feb 01, 2024	blackwell kimberly	sold (taxes)	-241,457	11.69	-20,655	chief executive officer
Feb 01, 2024	epperly melissa b,	acquired	-	-	75,000	chief financial officer

Which funds bought or sold ZNTL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-0.05	435,358	11,404,800	-%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	new	-	198,292	198,292	0.03%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-49.16	-4,646	5,215	-%
May 10, 2024	Covestor Ltd	added	75.00	-	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	8.86	37,020	316,477	-%
May 10, 2024	CITIGROUP INC	added	76.19	1,841,030	4,051,690	-%
May 10, 2024	BlackRock Inc.	reduced	-0.84	2,239,780	73,217,100	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-17.79	-11,737,100	69,322,300	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-37.27	-491,870	923,867	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	21,843	21,843	-%

Are Funds Buying or Selling ZNTL?

Are funds buying ZNTL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZNTL

No. of Funds

Unveiling Zentalis Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	5.1%	6	SC 13G/A
Feb 13, 2024	avidity partners management lp	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	7.56%	5,350,458	SC 13G/A
Feb 09, 2024	wellington management group llp	0.10%	68,791	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital international investors	4.0%	2,819,664	SC 13G/A
Jan 29, 2024	blackrock inc.	6.6%	4,684,975	SC 13G/A
Jan 25, 2024	state street corp	6.24%	4,417,056	SC 13G/A
Dec 11, 2023	eventide asset management, llc	16.34%	11,559,975	SC 13G/A
Nov 17, 2023	citadel advisors llc	5.1%	6	SC 13G

Recent SEC filings of Zentalis Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	144	Notice of Insider Sale Intent
May 09, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report

Peers (Alternatives to Zentalis Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Zentalis Pharmaceuticals Inc News

Latest updates

Zentalis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	1.0%	557	552	586	621	489	539	529	568	406	455	435	284	328	366	393	257	88.00	87.00	41.00
Current Assets	1.4%	504	497	528	564	410	452	434	468	301	351	378	259	306	345	373	238	66.00	69.00	27.00
Cash Equivalents	43.7%	40.00	28.00	111	267	36.00	43.00	43.00	55.00	31.00	60.00	41.00	49.00	29.00	56.00	93.00	96.00	64.00	67.00	25.00
Net PPE	-2.4%	6.00	6.00	6.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	5.00	2.00	2.00	1.00	0.00	0.00	1.00	1.00	0.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-13.6%	99.00	114	104	98.00	104	105	100	95.00	90.00	90.00	41.00	36.00	36.00	32.00	27.00	19.00	21.00	19.00	9.00
Current Liabilities	-21.0%	55.00	69.00	59.00	52.00	56.00	57.00	54.00	49.00	43.00	44.00	39.00	34.00	33.00	29.00	24.00	16.00	17.00	15.00	6.00
Shareholder's Equity	4.9%	459	437	482	523	386	434	429	473	316	364	394	248	293	333	366	238	-	-	32.00
Retained Earnings	1.1%	-878	-888	-827	-772	-659	-596	-541	-486	-418	-359	-309	-305	-250	-200	-160	-125	-99.12	-82.99	-37.33
Additional Paid-In Capital	1.0%	1,336	1,324	1,310	1,296	1,046	1,031	972	961	735	724	703	529	519	509	502	339	-	-	-
Shares Outstanding	0.3%	71.00	71.00	71.00	71.00	59.00	59.00	51.00	51.00	45.00	43.00	42.00	41.00	-	-	-	-	-	-	-
Minority Interest	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	24.00	24.00	25.00	-	-	7.00	7.00	-
Float	-	-	-	-	1,560	-	-	-	1,300	-	-	-	1,760	-	-	-	1,150	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-28.0%	-51,974	-40,599	-38,665	-79,275	-49,283	-37,329	-33,199	-43,027	-50,196	-37,021	-33,490	-46,113	-37,469	-27,357	-20,564	-22,033	-16,871	-13,191	-9,988	-6,958	-9,006
Share Based Compensation	-7.5%	12,833	13,880	13,867	13,342	13,733	9,612	10,317	16,764	10,147	8,471	7,656	9,919	9,691	7,887	7,249	7,681	329	212	155	121	129
Cashflow From Investing	246.3%	61,545	-42,060	-117,451	72,932	42,121	-11,894	20,018	-142,100	19,796	43,267	-141,443	66,603	13,458	-9,650	-137,890	-137,261	-31.00	-36.00	-107	-168	-41.00
Cashflow From Financing	-	7.00	-	309	236,621	373	49,741	589	209,455	1,258	12,267	166,570	-316	-	-594	155,899	191,660	13,474	-53.00	81,883	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ZNTL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
License Revenue	$ 40,560	$ 0
Operating Expenses
Research and development	49,585	48,584
General and administrative	15,740	16,369
Total operating expenses	65,325	64,953
Loss from operations	(24,765)	(64,953)
Other Income (Expense)
Investment and other income, net	34,948	4,109
Net income (loss) before income taxes	10,183	(60,844)
Income tax expense	143	108
Loss on equity method investment	0	2,310
Net income (loss)	10,040	(63,262)
Net loss attributable to noncontrolling interests	(28)	(43)
Net income (loss) attributable to Zentalis	$ 10,068	$ (63,219)
Earnings per share
Basic (in dollars per share)	$ 0.14	$ (1.07)
Diluted (in dollars per share)	$ 0.14	$ (1.07)
Weighted average common shares outstanding
Basic (in shares)	70,898	59,277
Diluted (in shares)	71,192	59,277

ZNTL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 37,616	$ 28,038
Marketable securities, available-for-sale	451,368	454,881
Prepaid expenses and other current assets	14,822	13,799
Total current assets	503,806	496,718
Property and equipment, net	5,679	5,819
Operating lease right-of-use assets	34,726	35,916
Prepaid expenses and other assets	6,851	6,818
Goodwill	3,736	3,736
Restricted cash	2,681	2,681
Total assets	557,479	551,688
Current liabilities
Accounts payable	10,502	14,926
Accrued expenses	44,296	54,441
Total current liabilities	54,798	69,367
Long-term lease liability	42,616	43,150
Other long-term liabilities	1,294	1,780
Total liabilities	98,708	114,297
Commitments and contingencies
EQUITY
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized; 71,011,982 and 70,765,554 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	70	70
Additional paid-in capital	1,336,416	1,323,576
Accumulated other comprehensive income	773	2,194
Accumulated deficit	(878,488)	(888,556)
Total stockholders’ equity	458,771	437,284
Noncontrolling interests	0	107
Total equity	458,771	437,391
Total liabilities and stockholders’ equity	$ 557,479	$ 551,688

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Kimberly Lynn Blackwell M.D.
WEBSITE	https://zentalis.com
INDUSTRY	Biotechnology
EMPLOYEES	156

Zentalis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Zentalis Pharmaceuticals Inc? What does ZNTL stand for in stocks?

ZNTL is the stock ticker symbol of Zentalis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zentalis Pharmaceuticals Inc (ZNTL)?

As of Mon May 13 2024, market cap of Zentalis Pharmaceuticals Inc is 834.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZNTL stock?

You can check ZNTL's fair value in chart for subscribers.

What is the fair value of ZNTL stock?

You can check ZNTL's fair value in chart for subscribers. The fair value of Zentalis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zentalis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZNTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zentalis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ZNTL is over valued or under valued. Whether Zentalis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Zentalis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZNTL.